{"entity":{"id":"john-seymour","kind":"person","name":"John F. Seymour","aka":[],"tldr":"Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL.","summary":"John Seymour was principal investigator of MURANO, the trial showing two years of venetoclax plus rituximab dramatically improves progression-free and overall survival compared with bendamustine-rituximab in relapsed CLL, the first randomised proof of venetoclax's benefit and the first fixed-duration targeted regimen. He co-led the first-in-human venetoclax studies with the Melbourne group that discovered BCL2 inhibition and leads haematology at Peter Mac.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Seymour%20JF%5BAuthor%5D%20venetoclax%20MURANO"}],"tags":["cll","venetoclax","australia"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing"],"targets":["bcl2","cd20"],"drugs":["venetoclax"],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-murano-venetoclax-rituximab-nejm-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital","institutionId":"peter-mac","specialisms":["Chronic lymphocytic leukaemia","Venetoclax","Lymphoma","BCL2 inhibition"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Seymour%20JF%5BAuthor%5D%20venetoclax%20MURANO"}],"papers":[{"title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia (MURANO)","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1713976"},{"title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","journal":"Lancet Oncology","year":2017,"doi":"10.1016/S1470-2045(17)30012-8"}],"orcid":"0000-0003-2188-6835"},"route":"/people/john-seymour/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"institution":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"paper":[{"id":"paper-murano-venetoclax-rituximab-nejm-2018","kind":"paper","name":"MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL","route":"/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/"}],"trial":[{"id":"murano","kind":"trial","name":"MURANO","route":"/trials/murano/"}]}}